JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (76)
2022
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
2021
-
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
HemaSphere, Vol. 5, Núm. 2
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 419-430
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
2016
-
Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse
Oncotarget, Vol. 7, Núm. 49, pp. 80664-80679
-
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
Leukemia Research, Vol. 40, pp. 1-9
-
Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma
Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217
-
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma
Blood, Vol. 128, Núm. 4, pp. 497-503
2015
-
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
British Journal of Haematology, Vol. 170, Núm. 6, pp. 804-813
-
Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma
Haematologica
-
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study
Haematologica, Vol. 100, Núm. 10, pp. 1294-1300
-
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
Leukemia, Vol. 29, Núm. 5, pp. 1186-1194
-
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution
Leukemia
2014
-
Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance
Haematologica, Vol. 99, Núm. 1, pp. 155-162
-
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial
The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206
-
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines
PLoS ONE, Vol. 9, Núm. 3
-
Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies
Haematologica, Vol. 99, Núm. 8, pp. 1365-1372
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234